Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) is a validated, weighted composite index used to quantify lupus disease activity at a point in time and track response to therapy. Twenty-four descriptors spanning neuropsychiatric, vascular, renal, musculoskeletal, mucocutaneous, serosal, immunologic, and constitutional domains are each scored present/absent within the prior 10 days (2K revision extends renal and rash descriptors to persistent findings) and summed into a single score. Rule out infection before attributing fever or cytopenias to lupus activity — cross-check with CURB-65 or SIRS if sepsis is a concern. When renal descriptors are positive, assess kidney function with eGFR and Urine Anion Gap. For inflammatory joint symptoms without other lupus features, compare against DAS28 and RA Classification Criteria to exclude concurrent RA.
Formula: Sum of weighted points (1, 2, 4, or 8) for each of 24 present descriptors within the prior 10 days.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
SLEDAI-2K scores 24 defined clinical and laboratory descriptors across eight organ systems, each recorded as present or absent within the 10 days preceding assessment (the 2000 revision, unlike the original SLEDAI, allows persistent proteinuria, rash, and alopecia to be scored as present even if unchanged from the prior visit, better capturing chronic active disease). Neuropsychiatric descriptors — seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and CVA — each carry the highest weight (8 points) reflecting their severity and impact, as does vasculitis. Musculoskeletal and renal descriptors — arthritis, myositis, urinary casts, hematuria, proteinuria, and pyuria — are weighted 4 points each. Mucocutaneous and serosal findings — new rash, alopecia, mucosal ulcers, pleurisy, and pericarditis — plus the two immunologic markers (low complement, increased anti-dsDNA binding) are weighted 2 points each. Constitutional and hematologic findings — fever, thrombocytopenia, and leukopenia — are weighted 1 point each, reflecting their lower specificity for lupus activity versus other causes.
Nearly every SLEDAI-2K descriptor requires active exclusion of a non-lupus explanation before it can be scored positive. Fever should not be scored if infection is present or more likely. Seizure should be scored only after excluding metabolic (uremia, hypoglycemia), infectious (meningitis), and drug-related causes. Cytopenias (thrombocytopenia, leukopenia) require exclusion of drug effect (especially from immunosuppressants themselves), and proteinuria attribution requires exclusion of other renal disease, medication effect, or urinary tract infection. This exclusion requirement is what makes SLEDAI-2K a clinical judgment tool rather than a simple checklist — two clinicians reviewing the same lab and imaging data can score differently if one attributes, say, thrombocytopenia to active lupus and the other to a recently started sulfonamide antibiotic. Document the reasoning for each positive descriptor, particularly for low-specificity findings like fever and cytopenias.
Add the point values of every positive descriptor to obtain the total SLEDAI-2K score (theoretical maximum around 105, though real-world scores rarely exceed 45). Interpret using commonly cited bands: 0 indicates no measurable activity, 1-5 mild activity, 6-10 moderate activity, 11-19 high activity, and ≥20 very high activity — though exact band cutoffs vary somewhat between cohorts and institutions, so use them as a general guide alongside clinical judgment rather than a rigid protocol. Beyond the absolute score, SLEDAI-2K is used to define flares in longitudinal follow-up. A commonly used definition (SELENA-SLEDAI flare index) considers a flare 'mild/moderate' when the score increases by 3 or more points, or 'severe' when it increases by 12 or more points or when specific severe descriptors newly appear (e.g., new CNS lupus, vasculitis, nephritis). Track the score serially at each visit — the trend and the specific descriptors driving a change matter more for management decisions than any single absolute value.
Nephrologists and rheumatologists co-managing lupus nephritis
Track renal descriptors (proteinuria, hematuria, urinary casts, pyuria) alongside complement and anti-dsDNA trends at each visit to detect renal flares early, since a rising SLEDAI driven by renal descriptors often precedes a measurable creatinine rise and should prompt urgent biopsy consideration or immunosuppression escalation.
Rheumatologists managing hydroxychloroquine, mycophenolate, or belimumab regimens
Serial SLEDAI-2K scores provide the objective evidence needed to justify escalating immunosuppression during a flare or, conversely, to support a cautious steroid or immunosuppressant taper once sustained low activity is documented over multiple visits.
Clinical research coordinators in lupus trials
Most modern SLE trials use SLEDAI-2K-based composite responder indices (SRI-4, BICLA) as primary endpoints, requiring precise baseline and follow-up scoring by trained assessors — this tool mirrors the calculation used in those protocols.
Rheumatology and neurology co-management teams
When a lupus patient develops new neurologic or psychiatric symptoms, systematically scoring the seven high-weight neuropsychiatric SLEDAI descriptors (after excluding infection, metabolic causes, and medication effects) helps determine whether CNS lupus is the likely driver and supports the case for aggressive treatment.
Hospitalists and rheumatology consult services
A febrile lupus patient with normal complement, no rising anti-dsDNA, and no other positive descriptors should raise suspicion for infection rather than flare — SLEDAI-2K's requirement to exclude infection before scoring fever formalizes this differential and prevents inappropriately escalating immunosuppression during an infection.
Patients and primary rheumatologists tracking chronic disease
A dated series of SLEDAI-2K scores across years of follow-up creates an objective record of disease trajectory that's far more useful for treatment decisions and specialist handoffs than subjective 'doing better/worse' notes alone.
Fever, cytopenias, seizure, and proteinuria all have common non-lupus explanations (infection, drug effect, other renal disease). Scoring a descriptor positive without documenting that these were considered and excluded undermines the score's validity and can lead to inappropriate immunosuppression escalation for what's actually an infection or drug reaction.
Unlike the original 1992 SLEDAI, which only counted new or recurrent findings, SLEDAI-2K scores these three mucocutaneous descriptors as present even if chronic and unchanged, better reflecting ongoing disease burden. This is a common point of confusion for clinicians trained on the older instrument.
Fatigue, Raynaud's phenomenon, and sicca symptoms — all common and burdensome lupus manifestations — are not captured by any SLEDAI-2K descriptor. A patient can have significant quality-of-life impact from lupus while scoring 0, so don't equate SLEDAI-2K score with overall disease burden or patient-reported wellbeing.
Serial immunologic monitoring (even when the clinical exam is quiet) can flag an impending flare before new organ-threatening descriptors appear, giving an opportunity for closer monitoring or early intervention rather than waiting for overt clinical deterioration.
A mild/moderate flare is generally defined as a ≥3-point increase in SLEDAI-2K; a severe flare as a ≥12-point increase or the new appearance of a severe descriptor (new nephritis, vasculitis, CNS lupus, myositis, or platelet count <60,000). Using these standardized thresholds, rather than gestalt impression, keeps flare documentation consistent across visits and providers.
Thrombocytopenia and leukopenia in a lupus patient are frequently drug-related (from azathioprine, mycophenolate, or other agents) rather than reflecting active hematologic lupus — the low weighting reflects this, but always check a recent medication history and drug levels before attributing cytopenia to disease activity.
Proteinuria >0.5g/24h is the SLEDAI-2K threshold, which requires a quantitative measurement (24-hour collection or spot urine protein-to-creatinine ratio), not a qualitative dipstick reading — dipstick alone can both under- and overestimate true proteinuria.
SLEDAI-2K measures current, reversible disease activity, not cumulative, irreversible organ damage from past flares or treatment toxicity (e.g., avascular necrosis, chronic kidney disease, cataracts from steroids). Use the SLICC/ACR Damage Index alongside SLEDAI-2K for a full longitudinal assessment.
SLEDAI-2K scores are commonly grouped as: 0 no activity, 1-5 mild activity, 6-10 moderate activity, 11-19 high activity, and ≥20 very high activity. A rise of ≥3 points from a prior visit indicates a mild/moderate flare, and ≥12 points (or a new severe descriptor) indicates a severe flare.
Use SLEDAI-2K at rheumatology follow-up visits for patients with an established SLE diagnosis to quantify current disease activity, detect flares, and guide immunosuppression titration or tapering decisions.
Every descriptor requires exclusion of non-lupus mimics (infection, drug effect, other organ disease), introducing inter-rater variability. The instrument doesn't capture fatigue, Raynaud's, sicca symptoms, or cumulative organ damage, and a score of 0 doesn't mean the patient is symptom-free.
For related assessments, see DAS28 Score, RA Classification (ACR/EULAR) and eGFR Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate DAS28-ESR to measure rheumatoid arthritis disease activity. Remission <2.6, low ≤3.2, moderate ≤5.1, high >5.1. Free treat-to-target calculator.
OpenRheumatologyScore the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria across joints, serology, acute-phase reactants, and duration. ≥6/10 classifies definite RA.
OpenClinicalCalculate eGFR with the CKD-EPI 2021 race-free formula to estimate kidney function and CKD stage from serum creatinine, age, and sex.
OpenEmergencyCalculate CURB-65 for community-acquired pneumonia severity to guide outpatient treatment, hospital admission, or ICU-level evaluation.
OpenNeuropsychiatric
Vascular
Musculoskeletal
Renal
Mucocutaneous
Serosal
Immunologic
Constitutional / Hematologic